In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of Avalara, Inc. (NYSE:AVLR),
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), NexPoint Residential
Trust, Inc. (NYSE:NXRT), Ferroglobe PLC (NASDAQ:GSM), China Online
Education Group (NYSE:COE), and S&W Seed Company (NASDAQ:SANW),
including updated fundamental summaries, consolidated fiscal
reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
AVLR DOWNLOAD:
http://Capital-Review.com/register/?so=AVLR SNSS DOWNLOAD:
http://Capital-Review.com/register/?so=SNSS NXRT DOWNLOAD:
http://Capital-Review.com/register/?so=NXRT GSM DOWNLOAD:
http://Capital-Review.com/register/?so=GSM COE DOWNLOAD:
http://Capital-Review.com/register/?so=COE SANW DOWNLOAD:
http://Capital-Review.com/register/?so=SANW
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine Avalara,
Inc. (NYSE:AVLR), Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS),
NexPoint Residential Trust, Inc. (NYSE:NXRT), Ferroglobe PLC
(NASDAQ:GSM), China Online Education Group (NYSE:COE), and S&W
Seed Company (NASDAQ:SANW) on a fundamental level and outlines the
overall demand for their products and services in addition to an
in-depth review of the business strategy, management discussion,
and overall direction going forward. Several excerpts from the
recently released reports are available to today's readers
below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. Percentage
calculations are performed after rounding. All amounts in millions
(MM), except per share amounts.
-----------------------------------------
AVALARA, INC. (AVLR) REPORT OVERVIEW
Avalara's Recent Financial Performance
For the twelve months ended December 31st, 2018
vs December 31st, 2017, Avalara reported revenue of $272.10MM vs
$213.16MM (up 27.65%) and analysts estimated basic earnings per
share -$1.95 vs -$11.39. Analysts expect earnings to be released on
May 14th, 2019. The report will be for the fiscal period ending
March 31st, 2019. The estimated EPS forecast for the next fiscal
year is -$0.63 and is expected to report on February 11th,
2020.
To read the full Avalara, Inc. (AVLR) report, download it here:
http://Capital-Review.com/register/?so=AVLR
-----------------------------------------
SUNESIS PHARMACEUTICALS, INC. (SNSS) REPORT
OVERVIEW
Sunesis Pharmaceuticals' Recent Financial
Performance
For the twelve months ended December 31st, 2018
vs December 31st, 2017, Sunesis Pharmaceuticals reported revenue of
$0.24MM vs $0.67MM (down 64.57%) and analysts estimated basic
earnings per share -$0.75 vs -$1.45. Analysts expect earnings to be
released on May 14th, 2019. The report will be for the fiscal
period ending March 31st, 2019. Reported EPS for the same quarter
last year was -$0.21. The estimated EPS forecast for the next
fiscal year is -$0.27 and is expected to report on March 5th,
2020.
To read the full Sunesis Pharmaceuticals, Inc. (SNSS) report,
download it here:
http://Capital-Review.com/register/?so=SNSS
-----------------------------------------
NEXPOINT RESIDENTIAL TRUST, INC. (NXRT) REPORT
OVERVIEW
NexPoint Residential Trust's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, NexPoint Residential Trust reported revenue
of $39.39MM vs $34.91MM (up 12.82%) and analysts estimated basic
earnings per share -$0.23 vs -$0.21. For the twelve months ended
December 31st, 2018 vs December 31st, 2017, NexPoint Residential
Trust reported revenue of $146.60MM vs $144.24MM (up 1.64%) and
analysts estimated basic earnings per share -$0.08 vs $2.53.
Analysts expect earnings to be released on April 30th, 2019. The
report will be for the fiscal period ending March 31st, 2019.
Reported EPS for the same quarter last year was $0.45. The
estimated EPS forecast for the next fiscal year is $2.08 and is
expected to report on February 18th, 2020.
To read the full NexPoint Residential Trust, Inc. (NXRT) report,
download it here:
http://Capital-Review.com/register/?so=NXRT
-----------------------------------------
FERROGLOBE PLC (GSM) REPORT OVERVIEW
Ferroglobe's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Ferroglobe reported revenue of $603.52MM vs
$468.22MM (up 28.90%) and basic earnings per share -$0.08 vs $0.04.
For the twelve months ended December 31st, 2018 vs December 31st,
2017, Ferroglobe reported revenue of $2,274.04MM vs $1,741.69MM (up
30.56%) and analysts estimated basic earnings per share $0.52 vs
-$0.00. Analysts expect earnings to be released on May 20th, 2019.
The report will be for the fiscal period ending March 31st, 2019.
The reported EPS for the same quarter last year was $0.21. The
estimated EPS forecast for the next fiscal year is $0.09 and is
expected to report on February 24th, 2020.
To read the full Ferroglobe PLC (GSM) report, download it here:
http://Capital-Review.com/register/?so=GSM
-----------------------------------------
CHINA ONLINE EDUCATION GROUP (COE) REPORT
OVERVIEW
China Online Education Group's Recent Financial
Performance
For the three months ended September 30th, 2018
vs September 30th, 2017, China Online Education Group reported
revenue of $44.14MM vs $35.49MM (up 24.39%) and analysts estimated
basic earnings per share -$0.60 vs -$1.05. For the twelve months
ended December 31st, 2018 vs December 31st, 2017, China Online
Education Group reported revenue of $166.61MM vs $130.33MM (up
27.83%) and analysts estimated basic earnings per share -$3.00 vs
-$4.50. Analysts expect earnings to be released on June 11th, 2019.
The report will be for the fiscal period ending March 31st,
2019.
To read the full China Online Education Group (COE) report,
download it here:
http://Capital-Review.com/register/?so=COE
-----------------------------------------
S&W SEED COMPANY (SANW) REPORT OVERVIEW
S&W Seed's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, S&W Seed reported revenue of $18.58MM
vs $20.53MM (down 9.51%) and analysts estimated basic earnings per
share -$0.09 vs -$0.02. For the twelve months ended June 30th, 2018
vs June 30th, 2017, S&W Seed reported revenue of $64.09MM vs
$75.37MM (down 14.98%) and analysts estimated basic earnings per
share -$0.21 vs -$0.67. Analysts expect earnings to be released on
May 8th, 2019. The report will be for the fiscal period ending
March 31st, 2019. The reported EPS for the same quarter last year
was $0.08. The estimated EPS forecast for the next fiscal year is
-$0.33 and is expected to report on September 19th, 2019.
To read the full S&W Seed Company (SANW) report, download it
here:
http://Capital-Review.com/register/?so=SANW
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Morena Zambada, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Apr 2024 to May 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From May 2023 to May 2024